Similar observations were made by Lachowietz et al., who reported a higher frequency of TET2 and a lower frequency of DNMT3A mutations in NPM1-mut AML patients ≥65 years compared to those ≤65 years [19]. Here, TET2 is linked to acute myeloid leukemia.